Pacira BioSciences (PCRX) Proxy Filing summary

Executive summary

• Reaffirmed commitment to shareholder value creation and outlined progress on the 5x30 strategy, targeting measurable objectives by 2030.

• Treated 2.5 million patients in 2025, aiming for 3 million annually by 2030.

• Achieved record-high 2025 GAAP and non-GAAP gross margins of 79% and 81%, respectively, with a goal of a five-point improvement over the 2024 baseline.

• Advanced clinical pipeline with key milestones expected in 2026, including Phase 3 and Phase 2 data readouts.

• Executed $150 million in stock repurchases in 2025, reducing outstanding shares from 47 to 41 million.

Voting matters and shareholder proposals

• DOMA Perpetual Capital Management nominated three director candidates for election at the 2026 Annual Meeting.

• The Nominating, Governance and Sustainability Committee will review the proposed nominees and provide recommendations in the definitive proxy statement.

• No shareholder action is required at this time; the date of the Annual Meeting has not been announced.

Board of directors and corporate governance

• Board and management have met with DOMA 12 times since January 2024 to discuss strategy and operations.

• The Board remains confident in its current strategy and will continue to act in the best interests of all shareholders.